Idera Pharmaceuticals, Inc. (IDRA) belonging to the Medical sector has surged 8.74% and closed its last trading session at $1.99.
The company reported its EPS on 03/09/2017. Currently, the stock has a 1 Year Price Target of $5.
The consensus recommendation, according to Zacks Investment research, is 1. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.
The Stock had a 1 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1 and 1 respectively.
Idera Pharmaceuticals, Inc. on 03/09/2017 reported its EPS as $0.01 with the analysts projecting the EPS of the stock as $-0.11. The company beat the analyst EPS Estimate with the difference of $0.12. This shows a surprise factor of 109.1%.
Many analysts have provided their estimated foresights on Idera Pharmaceuticals, Inc. Earnings, with 2 analysts believing the company would generate an Average Estimate of $-0.1.
Whereas they predicted High and Low Earnings Estimate as $-0.09 and $-0.11 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.11.
Analysts are also projecting an Average Revenue Estimate for Idera Pharmaceuticals, Inc. as $300 Million in the Current Quarter. This estimate is provided by 1 analysts.
The High Revenue estimate is predicted as 300 Million, while the Low Revenue Estimate prediction stands at 300 Million. The company’s last year sales total was 294 Million.
For the Current Quarter, the growth estimate for Idera Pharmaceuticals, Inc. is 9.1%, while for the Next Quarter the stock growth estimate is -18.2%.
The Company got Initiated by Wedbush on 6-Jan-16 to Outperform.
Insider Trades for Idera Pharmaceuticals, Inc. show that the latest trade was made on 3 Jan 2017 where Gowen (Maxine), the Director completed a transaction type “Buy” in which 7000 shares were traded at a price of $1.5.
2 analysts projected Price Targets for Idera Pharmaceuticals, Inc.. The analysts believe that the company stock price could grow as high as $6. The Low Price target projection by analysts is $4 and the Mean Price Target is $5.
Idera Pharmaceuticals, Inc. (IDRA) has the market capitalization of $286.22 Million. The company rocked its 52-Week High of $3.33 on Sep 26, 2016 and touched its 52-Week Low of $1.19 on May 10, 2016.
The stock has Return on Assets (ROA) of -68.4 percent. Return on Equity (ROE) stands at -76.7% and Return on Investment (ROI) of 0 percent.
The stock is currently showing YTD performance of 32.67 Percent. The company has Beta Value of 2.46 and ATR value of 0.11. The Weekly and Monthly Volatility stands at 4.94% and 6.59%.